The Silent Pandemic: How Antibiotic Resistance Threatens Us All
Genomic surveillance reveals antibiotic resistance among key pathogens like Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Vibrio cholerae is rising rapidly, with susceptibility to commonly used antibiotics often falling below 20%
Antibiotics have long been hailed as miracle drugs, saving countless lives by treating microbial infections that were once deadly. However, their efficacy is increasingly compromised by the emergence of antibiotic resistance, an evolutionary process that enable survival and growth despite antibiotic exposure. These resistant strains, often termed “superbugs”, complicate the treatment of routine infections, resulting in prolonged illness, increased healthcare costs, and higher mortality rates. Moreover, antibiotic resistance poses significant risks in clinical settings, undermining the success of surgeries, chemotherapy, and organ transplants due to the heightened likelihood of infections by resistant pathogens. Addressing this challenge is critical to preserving modern medical advances.
Our recent work, published in different journals, sheds light on understanding the functions that confer antibiotic resistance in pathogenic bacteria, the reasons behind its rapid spread, the major contributing factors, and the steps that can be taken to slow its progression (Microbiology Spectrum, February 2025; a preprint, which is under revision with a Nature group journal and; a paper that has been accepted for publication by the Journal of Bacteriology). Understanding this issue is the first step in joining the fight against antibiotic resistance because it truly is everyone’s problem.
Why antibiotic resistance should concern everyone
Antibiotic resistance arises when bacteria develop the ability to survive exposure to antibiotics that are intended to kill or inhibit them. This resistance can emerge through spontaneous genetic mutations or via the horizontal acquisition of resistance genes from other microorganisms. The consequence is a reduction in the efficacy of standard antimicrobial therapies, leading to prolonged infections, increased risk of complications, and higher mortality rates. Intracellular bacterial pathogens, such as Mycobacterium tuberculosis, primarily develop resistance through chromosomal mutations that alter antibiotic targets or metabolic pathways. In contrast, our 2023 study found that extracellular pathogens, including members of the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), frequently acquire resistance genes via horizontal gene transfer (The Proceeding of the National Academy of Science, August 2023). These genes often encode enzymatic mechanisms of antibiotic inactivation, such as beta-lactamases, which degrade or modify antibiotic molecules, rendering them ineffective.
The problem is exacerbated by overuse and misuse of antibiotics in both humans and animals, poor infection control, and lack of new antibiotic development. Without urgent global action through responsible antibiotic use, better hygiene, vaccination, surveillance, and research, the world may face a post-antibiotic era, where minor injuries or common infections could once again be deadly. Antibiotic resistance is a growing public health threat that requires awareness and action from all sectors of society.
Current situation globally and in India
Antimicrobial resistance (AMR) already claims over 1.27 million direct lives annually (with nearly 5 million deaths indirectly associated) and is projected to rise sharply, potentially causing as many as 10 million deaths per year by 2050 if unchecked. The global economic toll is staggering estimated at nearly USD 2 trillion annually by mid-century in healthcare and lost productivity.
In India, genomic surveillance data from our group (The Proceeding of the National Academy of Science, August 2023) reveal emerging threats: resistance among key pathogens like Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Vibrio cholerae is rising rapidly, with susceptibility to commonly used antibiotics such as fluoroquinolones, cephalosporins and carbapenems often falling below 20%. The ICMR’s 2023 national report, based on nearly 100,000 isolates, documents declining efficacy across last-resort drugs including imipenem and meropenem. Compounding the problem are easy over‑the‑counter antibiotic access, dense populations, poor sanitation, and fragmented surveillance systems.
Rapid spread of antibiotic resistance
Antibiotic resistance is accelerating globally due to a complex interplay of biological, behavioural, and systemic factors. One of the primary drivers is the overuse and misuse of antibiotics in both human medicine and agriculture. In many countries, antibiotics are frequently prescribed unnecessarily for viral infections, or purchased over the counter without prescriptions, contributing to selective pressure on bacteria to evolve resistance.
Poor infection prevention and control in hospitals, inadequate sanitation, and limited public awareness also enable the rapid spread of resistant bacteria. In India, factors such as high population density, widespread self-medication, unregulated pharmaceutical sales, and improper disposal of antibiotic waste in the environment further exacerbate the problem.
Additionally, antibiotics are extensively used in livestock and poultry not just to treat disease but also as growth promoters, leading to the development of resistance that can transfer to humans through food or environmental pathways. Global travel and trade also facilitate the cross-border spread of resistant strains. Without effective regulation, stewardship, and public education, these drivers will continue to fuel the rapid spread of antibiotic resistance, threatening the effectiveness of modern medicine and increasing the burden of untreatable infections.
Factors driving emergence, spread of antibiotic resistance
Several key environmental and clinical factors significantly contribute to the emergence and dissemination of antibiotic resistance among clinically relevant bacterial pathogens. These include exposure to sublethal concentrations of antibiotics, high microbial density, and chemical contamination all of which create selective pressures that favour the survival of resistant strains.
Our recent observations (Journal of Bacteriology) indicate that certain classes of antibiotics can induce the bacterial SOS response, a stress-induced pathway that promotes horizontal gene transfer (HGT). This mechanism facilitates the rapid dissemination of resistance determinants among both pathogenic and commensal bacteria, thereby amplifying the threat of multidrug resistance across microbial communities. The misuse and overuse of antibiotics such as prescribing them for viral infections, incorrect dosing, and incomplete treatment courses are major drivers of sublethal antibiotic exposure in bacterial populations. In many low- and middle-income countries (LMICs), the unregulated availability of antibiotics over the counter, often without a prescription, further exacerbates this issue. Collectively, these factors create a high-selection-pressure environment that accelerates the evolution and spread of resistant pathogens, underscoring the urgent and multifaceted nature of the global antibiotic resistance crisis.
How to slow down antibiotic resistance
Antibiotic resistance is a natural outcome of microbial evolution. While it cannot be entirely eliminated, its emergence and spread can be significantly slowed through a coordinated, multisectoral approach that includes healthcare, agriculture, policymaking, and public engagement. One of the most effective strategies is the implementation of antibiotic stewardship programs, which promote the rational and responsible use of antibiotics. These programs emphasise prescribing antibiotics only when clinically necessary, and ensuring the correct drug, dose, and duration are used.
Equally important is the rapid detection of resistance in clinical samples prior to treatment, allowing for more targeted and effective therapies. Public education and awareness campaigns play a crucial role in reducing inappropriate use, such as self-medication, and encouraging adherence to prescribed treatments. In healthcare settings, strict infection prevention and control measures, including hand hygiene, sanitation, and surveillance are essential to limit the transmission of resistant pathogens. Addressing environmental contamination from pharmaceutical manufacturing and agricultural runoff is another key component, as is strengthening global surveillance systems to monitor resistance patterns and inform policy.
Together, these efforts form a comprehensive strategy to preserve the effectiveness of antibiotics and safeguard public health for future generations.
Room for optimism
Despite the growing threat of drug-resistant bacteria, there is reason for optimism. Effective management relies on precise diagnosis and antimicrobial susceptibility testing to enable targeted treatment. Global research is accelerating the development of new antibiotics, alternative therapies such as bacteriophages and host-directed treatments, and antibiotic potentiators that enhance existing drugs. Breakthroughs in rapid diagnostics, genomics, and AI-driven drug discovery are also driving progress. Together, these innovations represent a hopeful path forward in the fight against antibiotic resistance.
